MMRF Leadership - Multiple Myeloma Research Foundation Leadership

MMRC Leadership

The MMRC leadership team is an exceptional group of individuals with a broad range of experience across industries and disciplines. Along with key leaders from the MMRF, this group selects and oversees the MMRC’s research efforts.

paul giusti headshot

Paul A. Giusti

President and Chief Executive Officer

Paul Giusti is the President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF), a world-renown cancer-research organization. Prior to the MMRF, Mr. Giusti worked as a Chief Executive Officer, leader, executive and entrepreneur for over 30 years; he has founded, managed and led a variety of businesses. Early in his career, Mr. Giusti worked as an executive for GE where he held a number of management positions with a wide range of responsibilities.

Mr. Giusti has worked closely with the MMRF since its founding in 1998. In addition to chairing the successful $100 million capital campaign, he has served as a consultant for a number of foundation projects, led several MMRF outreach efforts and spoken on behalf of the MMRF.

Mr. Giusti holds a Bachelor of Science degree from the Colorado School of Mines and an MBA from Harvard University.


Rob Miani

Chief Financial Officer

Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry.

Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positons in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.


Daniel Auclair, PhD

Senior Vice President of Research

Dr. Daniel Auclair, who managed the MMRF Multiple Myeloma Genomics Initiative from 2007-2010, has rejoined the company after three years at the Broad Institute of MIT and Harvard.

As senior leader in the Cancer Program at the Broad Institute, Dr. Auclair was involved with a wide range of academic and industry collaborations centered around cancer genomics and personalized medicine.

Prior to this, he spent a decade in the pharmaceutical industry, most notably at Bayer Healthcare where he led a number of cancer drug discovery efforts.

Dr. Auclair has been involved in cancer genomics efforts and drug discovery for more than 20 years. He has been honored as one of the 2017 PharmaVOICE 100. The PharmaVOICE 100 is an annual list of inspirational and innovative individuals recognized for their positive contributions to the life-sciences industry. He has been recognized for his ability to act as a “bridge across the Cancer Archipelago” fostering collaboration in myeloma advancements among academia, government agencies and pharma companies.

Dr. Auclair holds graduate and post-graduate degrees in Biochemistry and Nutrition from the University of Montreal and conducted postdoctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Center.


Karen Woolley

Clinical Operations Manager

Prior to joining the MMRF, Clinical Operations Manager Karen Woolley had over 15 years of experience in clinical research starting out as a research coordinator/data manager at Memorial Sloan Kettering Cancer Center and then moving into the role of a Clinical Study manager working on clinical trial Phases I-IV, at Roche, Pfizer, Eisai and Forrest Labs she has extensive experience in:

Drug Development
NDA Submissions
Audit Preparation
Audit Resolution
Project Management
Vendor Management
Relationship Management
Process Improvement

At the MMRF Karen as a Clinical Operations manager she is responsible for the overall day to day project management communications/support among the MMRF and MMRC clinical trials (Phase I-II), network sites and industry/CRO partners. She works with the CRO’s to ensure appropriate Project Plans are established and implemented and managed. Karen negotiates study budgets and assists with the execution of site contracts. Oversees the coordination and communications associated with trial meeting planning and drives trial execution according to MMRCC start up and enrollment benchmarks.

It’s exciting to work with the investigators and the Multiple Myeloma Project Managers at the consortium sites assisting in the opening of trials for new therapy which could be a potential cure or can extend someone’s life. Multiple Myeloma does not discriminate it effects everyone. I am very proud to be a part of an organization that is truly making a difference. Working with the multiple myeloma consortium sites and industry partners to get the results from the studies analyzed to finding the next piece to solve the puzzle.

Chris Wiliams

Chris Williams

Vice President of Business Development

Christopher Williams was named Vice President of Business Development at the MMRF in 2017 responsible for business development, partnership and joint venture efforts for the foundation. He is a business development leader with a strong scientific background, specializing in the pharmaceutical and diagnostics space. Most recently he served as the VP of Business Development at WaveSense where he was in charge of their US commercialization strategy and product expansion, as well as, being responsible for overseeing their strategic partner relationships.

Previously Chris was VP of Business Development at SkylineDx providing commercialization strategy for their oncology portfolio. With PerkinElmer, as the Market Segment Leader in Oncology he had responsibility for their cancer diagnostic products including strategy, launch activities, external presentations and marketing execution.

While at Millennium Pharmaceuticals Chris held roles in the Protein Science, Technology Development and Proteomics groups. He also had scientific roles at Schering-Plough and the Sandoz Research Institute.

Chris holds graduate and post-graduate degrees in Microbiology/Molecular Biology and Protein Biochemistry from Clemson University.